Article
Infectious Diseases
Dusten T. Rose, Alexander Moskhos, Arya Wibisono, Kelly R. Reveles
Summary: This study evaluated the impact of using MicroScan and VITEK 2 automated systems to determine vancomycin MIC values on the treatment of MRSA bacteremia. The results showed that the MicroScan group had a higher rate of vancomycin alternative therapy use compared to the VITEK 2 group, while the VITEK 2 group had a shorter median hospital stay.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Thiago Fauerharmel-Nunes, Ronald S. Flannagan, Mariya I. Goncheva, Arnold S. Bayer, Vance G. G. Fowler Jr, Liana C. C. Chan, Michael R. Yeaman, Yan Q. Xiong, David E. Heinrichs
Summary: Staphylococcus aureus, especially methicillin-resistant S. aureus, is often associated with persistent bacteremia (PB) during vancomycin therapy despite in vitro susceptibility. Comparisons of PB strains with those from vancomycin-resolving bacteremia (RB) would provide important insights into PB outcomes.
INFECTION AND IMMUNITY
(2023)
Article
Infectious Diseases
Hiroshi Sasano, Kazuhiko Hanada
Summary: This study aimed to investigate the clinical outcomes and evaluate the risk factors for mortality in adult patients treated with vancomycin for vancomycin-susceptible Enterococcus faecium bacteremia. The results showed that concurrent use of vasopressors may be an independent risk factor for mortality.
Review
Infectious Diseases
Hassan Ishaq, Wajeeha Tariq, Khawaja Muhammad Talha, Bharath Raj Varatharaj Palraj, M. Rizwan Sohail, Larry M. Baddour, Maryam Mahmood
Summary: Overall mortality and complicated bacteremia were not significantly associated with high vancomycin MICs in patients with MRSAB. Early mortality was significantly associated with low vancomycin MIC, while mortality in studies using broth microdilution method and need for mechanical ventilation were significantly associated with high vancomycin MIC. Further randomized controlled trials are needed to assess the predictive value of vancomycin MIC values for mortality and other adverse clinical outcomes in patients with MRSAB.
Article
Pharmacology & Pharmacy
Wesley D. Kufel, Katie A. Parsels, Bruce E. Blaine, Jeffrey M. Steele, Rahul Mahapatra, Kristopher M. Paolino, Stephen J. Thomas
Summary: This study aimed to evaluate the effectiveness and safety of vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia (MRSAB). The results showed that this regimen may be an effective and well-tolerated salvage option for persistent MRSAB.
Article
Infectious Diseases
Andrew S. Haynes, Holly Maples, Sarah Parker
Summary: Vancomycin remains the standard of care for treating methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in pediatrics due to lack of definitive evidence for a superior alternative. However, vancomycin's use is hindered by nephrotoxicity and the need for therapeutic drug monitoring. Promising alternatives with improved safety include daptomycin, ceftaroline, and linezolid, but their efficacy data is limited. Despite this, it is time for clinicians to reconsider vancomycin's place in clinical use, considering patient-specific factors and various etiologies of MRSA bacteremia.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
(2023)
Article
Immunology
Warren Rose, Michael Fantl, Matthew Geriak, Victor Nizet, George Sakoulas
Summary: Literature has shown the effectiveness of combination antimicrobial therapy in treating refractory MRSA bacteremia, but considerations need to be made on which regimens are more beneficial, potential harms, and which patients can benefit from more aggressive treatment. In addition, combination therapy for MRSA bacteremia does not need to be uniform throughout the treatment course, with options for early intensive treatment and later consolidation therapy.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
George Sakoulas
Summary: Given the difficulty of obtaining answers from randomized clinical trials for treating challenging bacteremic infections caused by methicillin-resistant Staphylococcus aureus, clinicians, microbiologists, and pharmacists need to collaborate to find new individualized antimicrobial therapies. One successful example involved using imipenem/cilastatin plus fosfomycin to treat a particularly stubborn MRSA bacteremia and spinal abscess.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Immunology
Courtney N. Nichols, Lynn C. Wardlow, Kelci E. Coe, Mohammad Mahdee E. Sobhanie
Summary: This study found no significant difference in the composite outcome of 60-day bacteremia recurrence, readmission, or inpatient infection-related mortality for patients with MRSA bacteremia retained on combination therapy versus those de-escalated to monotherapy.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Pharmacology & Pharmacy
Christopher Ross, Basir Syed, Joanna Pak, Vishal Jhanji, Jason Yamaki, Ajay Sharma
Summary: The study investigated the stability of vancomycin ophthalmic drops prepared in different solutions stored at room temperature or under refrigeration for 28 days. Results showed that vancomycin ophthalmic drops prepared using PBS, BSS, and normal saline were stable up to the tested time point of 28 days, irrespective of their storage temperature.
Review
Infectious Diseases
Chienhsiu Huang, Ihung Chen, Lichen Lin
Summary: Combination therapy with daptomycin plus ceftaroline may reduce mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. The combination therapy group had similar in-hospital mortality, duration of bacteremia, and adverse event rate compared to the monotherapy group, but had lower bacteremia recurrence.
Review
Pharmacology & Pharmacy
Diari Gilliam, Dominic Acosta, Martha L. Carvour, Carla Walraven
Summary: For patients with MRSA bacteremia, continuous intravenous infusion (CIV) of vancomycin led to faster achievement of therapeutic goals compared to intermittent infusion (IIV), and patients who could not reach therapeutic trough levels on IIV were able to do so when switched to CIV.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Engineering, Biomedical
Renee L. Tonkin, Anna Klockner, Adrian Najer, Carolina J. Simoes da Silva, Cecile Echalier, Marc S. Dionne, Andrew M. Edwards, Molly M. Stevens
Summary: This study develops a hierarchical microparticle system for bacteria-activated single- and dual-antibiotic drug delivery, effectively killing antibiotic-resistant bacteria.
ADVANCED HEALTHCARE MATERIALS
(2022)
Review
Medicine, General & Internal
Fatema Mahjabeen, Utsow Saha, Mayesha N. Mostafa, Farzana Siddique, Eram Ahsan, Sawsan Fathma, Anika Tasnim, Tasnim Rahman, Ridwan Faruq, Md Sakibuzzaman, Fahmida Dilnaz, Adrita Ashraf
Summary: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has become a major global health concern due to its increasing antimicrobial resistance. This review article compared the efficacy of different antimicrobial agents for treating MRSA-related bloodstream infections and found that the combination of ceftaroline and daptomycin showed better efficacy compared to standard monotherapy with vancomycin or daptomycin. High-dose daptomycin therapy was also found to be more effective in cases with reduced susceptibility to vancomycin. However, more large-scale clinical trials are needed to explore the effectiveness and adverse effects of newer agents like 13-lactams for routine therapy in MRSA bacteremia.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Review
Infectious Diseases
Joshua. B. Parsons, Annette. C. Westgeest, Brian. P. B. Conlon, Vance. G. Fowler
Summary: Methicillin-resistant Staphylococcus aureus (MRSA) is a deadly pathogen that can persist in the bloodstream for days despite appropriate antibiotics. Persistent MRSA bacteremia is common and associated with poor clinical outcomes. This review explores the factors related to host-pathogen interaction and discusses the clinical relevance of each element. Treatment options and diagnostic approaches for managing persistent MRSA bacteremia are also discussed.
Article
Pharmacology & Pharmacy
Amy Legg, Niamh Meagher, Sandra A. Johnson, Matthew A. Roberts, Alan Cass, Marc H. Scheetz, Jane Davies, Jason A. Roberts, Joshua S. Davis, Steven Y. C. Tong
Summary: The clinical risk factors for nephrotoxicity in Staphylococcus aureus bacteraemia are still unclear. In a clinical trial comparing standard therapy to combination therapy, it was found that the combination therapy group had a significantly higher incidence of acute kidney injury.
CLINICAL DRUG INVESTIGATION
(2023)
Article
Obstetrics & Gynecology
Melissa L. Constantine, Todd H. Rockwood, Leslie M. Rickey, Tamara Bavendam, Lisa Kane Low, Jerry L. Lowder, Alayne D. Markland, Gerald McGwin, Elizabeth R. Mueller, Diane K. Newman, Sara Putnam, Kyle Rudser, Ariana L. Smith, Ann E. Stapleton, Janis M. Miller, Emily S. Lukacz
Summary: This study aimed to validate the self-administered, multidimensional bladder health scales and function indices for research in adult women. The results showed that these measures are reliable and valid tools for assessing bladder health in women's health research.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2023)
Article
Microbiology
Guohua An, C. Buddy Creech, Nan Wu, Roger L. Nation, Kenan Gu, Demet Nalbant, Natalia Jimenez-Truque, William Fissell, Stephanie Rolsma, Pratish C. Patel, Amy Watanabe, Nicholas Fishbane, Carl M. J. Kirkpatrick, Cornelia B. Landersdorfer, Patricia Winokur
Summary: The population pharmacokinetic (PK) analysis of meropenem in 114 critically ill patients showed that the drug's clearance is affected by creatinine clearance and continuous renal replacement therapy, while volume of distribution is influenced by total bodyweight. The developed model serves as a valuable addition to the existing meropenem population PK models and is particularly useful for therapeutic drug monitoring programs with Bayesian forecasting. Monte Carlo simulations demonstrated that the dosing regimens of 2 g every 8 h with 3-h prolonged infusion (PI) and 4 g/day by continuous infusion (CI) are superior in terms of target attainment and potential toxicity when renal function information is unavailable.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Psychology, Developmental
Deepa R. Camenga, Zhenxun Wang, Haitao Chu, Sarah Lindberg, Siobhan Sutcliffe, Sonya S. Brady, Tamera Coyne-Beasley, Colleen M. Fitzgerald, Sheila Gahagan, Lisa Kane Low, D. Yvette LaCoursiere, Missy Lavender, Ariana L. Smith, Ann Stapleton, Bernard L. Harlow
Summary: This study examined the impact of antecedent sexual health factors on lower urinary tract symptoms (LUTS) in adolescent women. The findings indicated that the use of oral contraceptives, history of sexual intercourse, number of sexual partners, and condom use were associated with LUTS reported at age 19. However, these associations were attenuated after adjusting for condom use and number of sexual partners. The associations between sexual intercourse and number of sexual partners with LUTS were stronger among women with >= 3 sexual partners.
JOURNAL OF ADOLESCENT HEALTH
(2023)
Article
Pharmacology & Pharmacy
Medha D. Joshi, Paulina Iacoban, Marc H. Scheetz
Summary: This study successfully encapsulated vancomycin in polyethylene glycol-coated liposomes (PEG-VANCO-lipo) and compared its effects with standard vancomycin. The results showed that PEG-VANCO-lipo resulted in lower levels of kidney injury, as indicated by decreased levels of KIM-1 in urine and reduced plasma vancomycin concentration. These findings suggest that PEG-VANCO-lipo has a high potential to decrease the nephrotoxicity of vancomycin clinically.
Article
Microbiology
Giancarlo Atassi, Rachel Medernach, Marc Scheetz, Sophia Nozick, Nathaniel J. Rhodes, Megan Murphy-Belcaster, Katherine R. Murphy, Arghavan Alisoltani, Egon A. Ozer, Alan R. Hauser
Summary: Resistance to aminoglycosides in Pseudomonas aeruginosa remained constant over 2 decades, indicating the effectiveness of antibiotic stewardship programs. Clinically relevant AME genes were found in 14% of isolates, and mutations in mexZ and armZ genes were common. These findings highlight the ongoing problem of aminoglycoside resistance and suggest potential targets for novel therapeutics.
MICROBIOLOGY SPECTRUM
(2023)
Article
Microbiology
Jack Chang, Gwendolyn M. Pais, Sylwia Marianski, Kimberly Valdez, Emily Lesnicki, Erin F. Barreto, Marc H. Scheetz
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Microbiology
Erin F. Barreto, Jack Chang, Andrew D. Rule, Kristin C. Mara, Laurie A. Meade, Johar Paul, Paul J. Jannetto, Arjun P. Athreya, Marc H. Scheetz, BLOOM Study Group
Summary: A population pharmacokinetic model for cefepime was developed and validated for critically ill patients. The study highlighted the importance of using cystatin C in predicting cefepime clearance.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Gwendolyn M. Pais, Sylwia Marianski, Kimberly Valdez, Renz Paulo Melicor, Jiajun Liu, Roxane Rohani, Jack Chang, Steven Y. C. Tong, Joshua S. Davis, Marc H. Scheetz
Summary: The study found that combining flucloxacillin with vancomycin in a rat model caused more severe kidney injury compared to vancomycin alone. Conversely, the combination of vancomycin with imipenem-cilastatin had a nephroprotective effect.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Immunology
Stephen P. Bergin, Roy F. Chemaly, Sanjeet S. Dadwal, Joshua A. Hill, Yeon Joo Lee, Ghady Haidar, Alfred Luk, Alexander Drelick, Peter Chin-Hong, Esther Benamu, Fareed Khawaja, Deepa Nanayakkara, Genovefa A. Papanicolaou, Catherine Butkus Small, Monica Fung, Michelle A. Barron, Thomas Davis, Micah T. Mcclain, Eileen K. Maziarz, Deng B. Madut, Armando D. Bedoya, Daniel L. Gilstrap, Jamie L. Todd, Christina E. Barkauskas, Robert Bigelow, Jeffrey D. Leimberger, Ephraim L. Tsalik, Olivia Wolf, Mona Mughar, Desiree Hollemon, Radha Duttagupta, Daniel S. Lupu, Sivan Bercovici, Bradley A. Perkins, Timothy A. Blauwkamp, Vance G. Fowler, Thomas L. Holland
Summary: Non-invasive plasma microbial cell-free DNA sequencing significantly increased diagnostic yield in immunocompromised patients with pneumonia undergoing bronchoscopy and extensive microbiologic and molecular testing.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Infectious Diseases
Jack Chang, Ardita Tasellari, Jamie L. Wagner, Marc H. Scheetz
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2023)
Article
Infectious Diseases
Jack Chang, Jiajun Liu, Mohammad H. Alshaer, Veena Venugopalan, Nicole Maranchick, Charles A. Peloquin, Nathaniel J. Rhodes, Marc H. Scheetz
Summary: A study was conducted to investigate the variability in cefepime exposures among real-world ICU patients using modeling and simulations. The results showed wide variations in cefepime exposure among patients with similar kidney function estimates. Current population adjustment schemes based solely on creatinine clearance may result in unintended high and low drug exposures, raising concerns about safety and efficacy.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Correction
Immunology
Nick Anagnostou, Sophia Archuleta, Eugene Athan, Lauren Barina, Emma Best, Max Bloomfield, Jennifer Bostock, Carly Botheras, Asha Bowen, Philip Britton, Hannah Burden, Anita Campbell, Hannah Carter, Matthew Cheng, Ka Lip Chew, Ivor Russel Lee Ming Chong, Geoffrey Coombs, Peter Daley, Nick Daneman, Jane Davies, Joshua Davis, Yael Dishon-Benattar, Ravindra Dotel, Adrian Dunlop, Felicity Flack, Katie Flanagan, Hong Foo, Nesrin Ghanem-Zoubi, Stefano Giulieri, Anna Goodman, Jennifer Grant, Daniel Gregson, Stephen Guy, Amanda Gwee, Erica Hardy, Andrew Henderson, George Heriot, Benjamin Howden, Fleur Hudson, Jennie Johnstone, Shirin Kalimuddin, Dana de Kretser, Andrea Kwa, Todd Lee, Amy Legg, Roger Lewis, Martin Llewelyn, Thomas Lumley, David Lye, Derek MacFadden, Robert Mahar, Isabelle Malhame, Michael Marks, Julie Marsh, Marianne Martinello, Gail Matthews, Colin McArthur, Anna McGlothlin, Genevieve McKew, Brendan McMullan, Zoe McQuilten, Eliza Milliken, Jocelyn Mora, Susan Morpeth, Srinivas Murthy, Clare Nourse, Matthew O'Sullivan, David Paterson, Mical Paul, Neta Petersiel, Lina Petrella, Sarah Pett, David Price, Jason Roberts, James Owen Robinson, Benjamin Rogers, Benjamin Saville, Matthew Scarborough, Marc Scheetz, Oded Scheuerman, Kevin Schwartz, Simon Smith, Thomas Snelling, Marta Soares, Christine Sommerville, Andrew Stewardson, Neil Stone, Archana Sud, Robert Tilley, Steven Tong, Rebecca Turner, Jonathan Underwood, Sebastiaan van Hal, Lesley Voss, Genevieve Walls, Rachel Webb, Steve Webb, Lynda Whiteway, Heather Wilson, Terence Wuerz, Dafna Yahav
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Biochemical Research Methods
John Takyi-Williams, Abbie D. Leino, Ruiting Li, Kevin J. Downes, Athena F. Zuppa, Amanda Bwint, Bo Wen, Duxin Sun, Marc H. Scheetz, Manjunath P. Pai
Summary: This study developed a bioanalytical method for the simultaneous quantification of multiple antibiotics from VAMS, which can facilitate pharmacokinetic/pharmacodynamic studies.
Article
Microbiology
Roxane Rohani, Paul R. Yarnold, Marc H. Scheetz, Michael N. Neely, Mengjia Kang, Helen K. Donnelly, Kay Dedicatoria, Sophie H. Nozick, Rachel L. Medernach, Alan R. Hauser, Egon A. Ozer, Estefani Diaz, Alexander V. Misharin, Richard G. Wunderink, Nathaniel J. Rhodes
Summary: This study aimed to investigate the difference in target attainment of meropenem between plasma and epithelial lining fluid (ELF). The study found that some patients did not achieve the target attainment in both plasma and ELF, and those who achieved target attainment in plasma did not necessarily have the same effect in ELF. Patients with a higher creatinine clearance rate may have poorer target attainment in ELF. Additionally, the dosage and loading dose may also affect the target attainment.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)